BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:12 PM
 | 
Apr 17, 2008
 |  BC Extra  |  Clinical News

Wyeth, Elan AD trial placed on hold

Wyeth (NYSE:WYE) and partner Elan (NYSE:ELN) said FDA placed on hold a U.S. Phase II trial of ACC-001 to treat Alzheimer's disease (AD) after a patient in a similar European Phase II trial was hospitalized with skin lesions. Wyeth...

Read the full 193 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >